BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AbbVie (ABBV) Plans to Focus on Specialty Drugs


1/4/2013 7:36:16 AM

AbbVie Inc. (ABBV), the drug unit that split from parent Abbott Laboratories (ABT) on Jan. 1, will seek treatments for unmet medical needs in a push to grow sales in 2015, the company’s new chief financial officer said. The competition is less keen to find drugs for conditions with few current therapies than for primary care, CFO William Chase said today in an interview in New York. AbbVie will focus on these illnesses, such as Parkinson’s and endometriosis, a disease of the uterus, where the North Chicago, Illinois-based company already has treatments under development, he said. Abbott split off AbbVie as a way to let investors choose between a medical products company that makes devices, diagnostics and nutrition products, and AbbVie, a drugmaker based largely around Humira, a best-selling rheumatoid arthritis injection that generated $7.93 billion in 2011. “We’re not going to be a primary care company going forward,” Chase said. “What we’re really looking for is specialty segments.” The goal is for those products to come on line in 2015, Chase said. “In 2015, the pipeline will kick in and at which point we’re confident AbbVie will return to growth, Chase said. Until then, sales likely will be little changed. The company over the next two years will lose about $2.5 billion of what it projects will be $18 billion in 2013 revenue as patents expire, Chase said. The sales loss will be offset by more revenue from Humira and Androgel, a testosterone product. AbbVie, which began trading yesterday, declined less than 1 percent to $34.83 at the close in New York.

Read at Bloomberg

Bloomberg
AbbVie
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES